460 related articles for article (PubMed ID: 20100187)
21. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
22. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
Goldberg A; Confino-Cohen R
J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
[TBL] [Abstract][Full Text] [Related]
23. An increase in serum tryptase even below 11.4 ng/mL may indicate a mast cell-mediated hypersensitivity reaction: a prospective study in Hymenoptera venom allergic patients.
Borer-Reinhold M; Haeberli G; Bitzenhofer M; Jandus P; Hausmann O; Fricker M; Helbling A; Müller U
Clin Exp Allergy; 2011 Dec; 41(12):1777-83. PubMed ID: 22092437
[TBL] [Abstract][Full Text] [Related]
24. Basal serum tryptase as risk assessment for severe Hymenoptera sting reactions in elderly.
Guenova E; Volz T; Eichner M; Hoetzenecker W; Caroli U; Griesinger G; Burow G; Mitev V; Biedermann T
Allergy; 2010 Jul; 65(7):919-23. PubMed ID: 20121769
[TBL] [Abstract][Full Text] [Related]
25. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
[TBL] [Abstract][Full Text] [Related]
26. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy.
White KM; England RW
Ann Allergy Asthma Immunol; 2008 Oct; 101(4):426-30. PubMed ID: 18939733
[TBL] [Abstract][Full Text] [Related]
27. Impact of Hymenoptera venom allergy and the effects of specific venom immunotherapy on mast cell metabolites in sensitized children.
Cichocka-Jarosz E; Sanak M; Szczeklik A; Brzyski P; Pietrzyk JJ
Ann Agric Environ Med; 2014; 21(2):294-301. PubMed ID: 24959779
[TBL] [Abstract][Full Text] [Related]
28. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy.
Bonadonna P; Zanotti R; Caruso B; Castellani L; Perbellini O; Colarossi S; Chilosi M; Dama A; Schiappoli M; Pizzolo G; Senna G; Passalacqua G
J Allergy Clin Immunol; 2008 Jan; 121(1):256-7. PubMed ID: 18206512
[No Abstract] [Full Text] [Related]
29. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
Bilò MB; Severino M; Cilia M; Pio A; Casino G; Ferrarini E; Campodonico P; Milani M
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):57-61. PubMed ID: 19663128
[TBL] [Abstract][Full Text] [Related]
30. Hymenoptera Anaphylaxis as a Clonal Mast Cell Disorder.
Bonadonna P; Scaffidi L
Immunol Allergy Clin North Am; 2018 Aug; 38(3):455-468. PubMed ID: 30007463
[TBL] [Abstract][Full Text] [Related]
31. Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected.
Bonadonna P; Zanotti R; Pagani M; Bonifacio M; Scaffidi L; Olivieri E; Franchini M; Reccardini F; Costantino MT; Roncallo C; Mauro M; Boni E; Rizzini FL; Bilò MB; Marcarelli AR; Passalacqua G
J Allergy Clin Immunol Pract; 2018; 6(4):1368-1372. PubMed ID: 29258788
[TBL] [Abstract][Full Text] [Related]
32. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and treatment of allergy to hymenoptera venoms.
Hamilton RG
Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):323-9. PubMed ID: 20543672
[TBL] [Abstract][Full Text] [Related]
34. Basal serum tryptase level correlates with severity of hymenoptera sting and age.
Kucharewicz I; Bodzenta-Lukaszyk A; Szymanski W; Mroczko B; Szmitkowski M
J Investig Allergol Clin Immunol; 2007; 17(2):65-9. PubMed ID: 17460943
[TBL] [Abstract][Full Text] [Related]
35. [Accelerated desensitization for hymenoptera venom allergy in 30 hours: efficacy and safety in 150 cases].
van der Brempt X; Ledent C; Mairesse M
Rev Med Brux; 1997 Jun; 18(3):120-4. PubMed ID: 9273600
[TBL] [Abstract][Full Text] [Related]
36. High sensitivity of basophils predicts side-effects in venom immunotherapy.
Kosnik M; Silar M; Bajrovic N; Music E; Korosec P
Allergy; 2005 Nov; 60(11):1401-6. PubMed ID: 16197472
[TBL] [Abstract][Full Text] [Related]
37. Changes in gene expression caused by insect venom immunotherapy responsible for the long-term protection of insect venom-allergic patients.
Niedoszytko M; Bruinenberg M; de Monchy J; Weersma RK; Wijmenga C; Jassem E; Elberink JN
Ann Allergy Asthma Immunol; 2011 Jun; 106(6):502-10. PubMed ID: 21624750
[TBL] [Abstract][Full Text] [Related]
38. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
39. New developments in the diagnosis and treatment of hymenoptera venom allergy.
Müller UR
Int Arch Allergy Immunol; 2001 Apr; 124(4):447-53. PubMed ID: 11340327
[TBL] [Abstract][Full Text] [Related]
40. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
